Drug Research in Inhibiting BCL6 in Ovarian Cancer

Quinn E. Beek  
*University of New Hampshire, Durham*

Sarah Walker  
*University of New Hampshire, Durham*

Follow this and additional works at: [https://scholars.unh.edu/honors](https://scholars.unh.edu/honors)

**Recommended Citation**  
[https://scholars.unh.edu/honors/737](https://scholars.unh.edu/honors/737)

This Senior Honors Thesis is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository. It has been accepted for inclusion in Honors Theses and Capstones by an authorized administrator of University of New Hampshire Scholars' Repository. For more information, please contact Scholarly.Communication@unh.edu.
Drug Research in Inhibiting BCL6 in Ovarian Cancer

Honors Thesis

Quinn Beek
Biochemistry, Molecular and Cellular Biology

Dr. Sarah Walker
Molecular, Cellular, and Biomedical Sciences
Abstract

Ovarian cancer has a survival rate of 50 percent just five years after being diagnosed (Nguyen et al. 2020). Finding new ways to treat ovarian cancer is important to increase the survival of patients who have been diagnosed. BCL6 is a transcription factor that is involved with metastasis and promoting chemotherapy resistant cancer cells. Finding a way to inhibit BCL6 could help prevent the things listed above and lead to a new treatment for patients with ovarian cancer. Researching genes that BCL6 regulates may offer new insights into treatments that can be researched to see if they are effective in inhibiting BCL6, which was the focus of my research. Using bioinformatics and cell culturing I researched drugs that had the possibility of inhibiting BCL6 and tested their effectiveness against ovarian cancer cell lines.